Keywords: Tumors (Pre-Treatment), Cancer, biomarker
Motivation: The isocitrate dehydrogenase (IDH)-genotype is a central determinant for the diagnosis, therapy and management of patients with adult-type diffuse glioma.
Goal(s): To investigate spatial tumor characteristics using an U-Net-based CNN and to evaluate its diagnostic potential for predictive IDH-genotyping.
Approach: Participants with treatment-naïve glioma were investigated using an U-Net-based CNN based on a standard MRI protocol computing a compartmental tumor mass (CTM)-ratio.
Results: A total of 207 patients (IDH-mutant, 72, IDH wild-type, 135) with treatment-naïve glioma were evaluated. IDH-mutated glioma presented greater CTM-ratio (P<.001) unlike IDH wild-type glioblastoma (P<.001) – which determined the IDH-genotype with excellent diagnostic performance (AUC=0.85, P<.001).
Impact: We performed DL-based spatial mapping of treatment-naïve glioma and computed the CTM-ratio for the evaluation of spatial tumor characteristics, which enabled robust classification of the IDH-genotype – with implications for the clinical management of adult-type glioma.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords